You have a choice. Choose AlignRT®.
AlignRT is a technology that helps precisely target your cancer – even if you move – to help protect surrounding healthy tissue including your heart.
AlignRT is an innovative technology which increases treatment accuracy and patient comfort during radiation therapy. Using a 3D camera system, AlignRT tracks your body surface in real time and pinpoints your radiation treatment to a specific area, dramatically reducing the risk of side effects and unwanted secondary health conditions.
Studies suggest that 27% of patients have experienced heart blood flow defects because of their radiation treatment.
Only AlignRT’s technology, with its Triple Shield System, is designed to work with the radiation delivery system to attack cancer and guard against unwanted side effects in three ways:
With AlignRT you can safely complete your radiation therapy and be one step closer to confidently putting cancer behind you.
Unlike traditional radiation technology, AlignRT’s advanced 3-D cameras provide an automated safety monitoring system that can stop the treatment if you move out of the desired treatment position.
It tracks if you move the width of a folded piece of paper and doesn’t need tattoos or marks to ensure accurate delivery. Because of its exceptional accuracy, AlignRT is used in 9 of the top 10 “Best Hospitals for Cancer” as tracked by US and News & World Report.
Over 1,700 Vision RT clinical systems are deployed worldwide, including in 80% of the top 50 US News “Best Hospitals for Cancer”. Over 80 clinical studies using Vision RT’s AlignRT technology have been published.
In this video, listen to radiation specialists sharing their insights about AlignRT, how it is becoming the new standard of radiation therapy and the benefits it can provide you.
Marks et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):214-23
Zagar et al. Utility of Deep inspiration breath-hold for left sided breast radiation therapy in preventing early cardiac perfusion defects – A Prospective Study. Int J Radiat Oncol Biol Phys. 2017